Truncus Arteriosus News and Research

RSS

Hospital size not the only factor in pediatric heart surgery outcomes

A study of pediatric heart surgery centers across the United States has demonstrated that, when it comes to successful surgery, it's not just the size of the program that matters in determining quality outcomes.

29 Jan 2024

World's first partial heart transplant performed at Duke Health

A team at Duke Health has performed what is believed to be the world's first partial heart transplant, with the living arteries and valves from a freshly donated heart fused onto a patient's existing heart.

8 Sep 2022

News briefs from featured presentations at Cardiology 2012

Pediatric cardiology researchers and clinicians from almost 50 centers from across the U.S. and around the world are gathering at the Cardiology 2012 Conference sponsored by The Children's Hospital of Philadelphia on Feb. 22-26 in Orlando, Fla.

27 Feb 2012

CryoPatch SG pulmonary human cardiac patch receives FDA clearance for 5-year shelf-life extension

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.

9 Aug 2010

Researchers find retinoic acid regulates SHF tissue formation

Researchers at the Keck School of Medicine of the University of Southern California have identified a key cellular mechanism that guides embryonic heart tissue formation-a process which, if disrupted, can lead to a number of common congenital heart defects.

18 Mar 2010

Transcatheter valve may eliminate repeat surgeries in children with heart defects; multicenter study shows good outcomes

Children born with certain heart defects have impaired blood flow from the right ventricle to the pulmonary artery leading to the lungs, requiring implanted devices (known as right-ventricular outflow tract conduits) to maintain the flow. However, these conduits fail over time, and children typically face multiple open-heart operations during their lives to reopen the passage.

27 Oct 2009

CryoValve SG aortic human heart valve receives Humanitarian Use Device designation

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug Administration (FDA) for its CryoValve® SG aortic human heart valve.

6 Oct 2009

CryoLife's SynerGraft technology effective in removing donor cells and cellular remnants from the tissue

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced the first three implantations of the CryoPatch((R)) SG pulmonary human cardiac patch since FDA clearance.

19 Aug 2009

Cryolife receives 510(k) clearance from FDA for CryoPatch SG pulmonary human cardiac patch

CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CryoPatch((R)) SG pulmonary human cardiac patch.

12 Aug 2009